Nivolumab-associated acute glomerulonephritis: a case report and literature review

BMC Nephrology

Volumn 17, Issue 1, 2016, Pages 1-6

  Jung, Kyungsuk ^a   Zeng, Xu ^b   Bilusic, Marijo ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Autoimmune nephritis; Case report; Immunotherapy; Nivolumab; Renal cell carcinoma

Indexed keywords

CREATININE; METHYLPREDNISOLONE; NIVOLUMAB; PAZOPANIB; POTASSIUM; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GLOMERULONEPHRITIS; ACUTE KIDNEY FAILURE; AGED; ANKLE EDEMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; FATIGUE; FOLLOW UP; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FUNCTION; LOSS OF APPETITE; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; SYMPTOM; SYSTEMIC THERAPY; UREA NITROGEN BLOOD LEVEL; WEAKNESS; WEIGHT GAIN; CHEMICALLY INDUCED; GLOMERULONEPHRITIS; KIDNEY TUMOR; RENAL CELL CARCINOMA;

ACUTE KIDNEY INJURY; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GLOMERULONEPHRITIS; HUMANS; KIDNEY NEOPLASMS; MALE;

EID: 84997418192     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-016-0408-2     Document Type: Article

References (20)

1. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889-94.
2. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33.
3. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-74.
4. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015-29.
5. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011;3(111):111-20.
6. Opdivo (Nivolumab). Last Accessed 27 May 2016.
7. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
8. Borghaei H, Paz-Ares L, Horn L, Spiegel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39.
9. Robert C, Schachter J, Long GV, Arance A, Grobb JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2512-32.
10. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44.
11. Fadel F, Karoui KE, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Eng J Med. 2009;361(2):211-2.
12. Forde PM, Rock K, Wilson G, O'Byrne KJ. Ipilimumab-induced immune-related renal failure - A case report. Anticancer Res. 2012;32(10):4607-8.
13. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. doi:10.1371/journal.pone.0053745.
14. Izzedine H, Guetin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Invest New Drugs. 2014;32:769-73.
15. Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22(3):e84-7. doi:10.1097/MJT.0b013e3182a32ddc.
16. Vandiver JW, Singer Z, Harshberger C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol. 2000; doi:10.1007/s11523-016-0426-9.
17. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Urqurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; doi: 10.1016/j.ejca.2016.02.025.
18. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28:1140-4.
19. Arriola E, Wheater M, Krisnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology. 2015;4(1):e1040218. doi:10.1080/2162402X.2015.1040218.
20. Amin A, Depril V, Hamid O, Wolchok J, Maio M, Neyns B, et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development of maintenance of ipilimumab clinical activity. J Clin Oncol. 2009;27:abstr 9037.